Agios Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Agios Pharmaceuticals, Inc.
Agios’s Sarah Gheuens talks to In Vivo about the responsibility of providing new therapies to rare disease populations, building trust with historically underserved communities, and why she loves working with small molecules.
The sponsors of six drugs that are nearing the end of the regulatory review cycle in the EU could this week be asked to explain why the European Medicines Agency should recommend approving their products.
Leadership change comes after CEO Jackie Fouse, who will serve as board chair, oversaw the sale of Agios' cancer portfolio, a reorganization and a shift in therapeutic focus to rare diseases.
Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.